Experts: HCV elimination requires less restrictions, more price negotiation
Dore GJ, et al. J Hepatol. 2017;doi:10.1016/j.jhep.2017.03.035.
April 14, 2017
Researchers compared estimated national costs of direct-acting antiviral therapy between Germany and Australia to clarify what steps may be necessary to achieve the WHO hepatitis C elimination goals, according to a recently published editorial.
April 14, 2017
Researchers compared estimated national costs of direct-acting antiviral therapy between Germany and Australia to clarify what steps may be necessary to achieve the WHO hepatitis C elimination goals, according to a recently published editorial.
“The ambitious targets for HCV elimination set by WHO are achievable in many countries globally, but will require researchers, healthcare providers, policy makers, the affected community and the pharmaceutical industry in other countries to work together to make this happen,” Gregory J. Dore, PhD, and Jason Grebely, PhD, from the Kirby Institute, University of New South Wales, Sydney, wrote in their editorial.
No comments:
Post a Comment